Jeffery W Kelly Selected Research

Diflunisal (Dolobid)

12/2013	Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.
8/2011	Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity.
1/2008	Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses.
12/2006	Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.
12/2006	Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis.
5/2004	Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffery W Kelly Research Topics

Disease

53	Amyloidosis 01/2022 - 12/2002
23	Alzheimer Disease (Alzheimer's Disease) 12/2021 - 04/2002
16	Familial Amyloid Neuropathies (Familial Amyloid Polyneuropathy) 01/2021 - 04/2002
12	Cardiomyopathies (Cardiomyopathy) 11/2019 - 11/2003
12	Familial Amyloidosis (Hereditary Amyloidosis) 09/2017 - 07/2003
11	Proteostasis Deficiencies 01/2022 - 12/2005
11	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2021 - 09/2003
9	Polyneuropathies (Polyneuropathy) 01/2021 - 07/2002
9	Amyloid Plaque 10/2018 - 10/2004
9	Gaucher Disease (Gaucher's Disease) 08/2014 - 11/2002
7	Transthyretin-Related Hereditary Amyloidosis 01/2022 - 05/2004
5	Lysosomal Storage Diseases (Lysosomal Storage Disease) 03/2013 - 05/2006
4	Disease Progression 10/2021 - 06/2012
4	Inflammation (Inflammations) 01/2021 - 04/2004
4	Parkinson Disease (Parkinson's Disease) 01/2021 - 08/2003
4	Immunoglobulin Light-chain Amyloidosis 01/2019 - 10/2012
4	Amyloid Neuropathies (Amyloid Neuropathy) 09/2017 - 11/2003
3	Cystic Fibrosis (Mucoviscidosis) 01/2020 - 11/2006
2	Lewy Body Disease (Lewy Body Dementia) 10/2021 - 05/2006
2	Rare Diseases (Rare Disease) 01/2021 - 10/2005
2	Communicable Diseases (Infectious Diseases) 01/2020 - 12/2011
2	Heart Failure 11/2019 - 06/2013
2	Inborn Genetic Diseases (Disease, Hereditary) 12/2013 - 12/2003
2	Inclusion Body Myositis 10/2013 - 07/2009
2	Doyne honeycomb retinal dystrophy 11/2012 - 12/2011
2	Macular Degeneration (Age-Related Maculopathy) 11/2012 - 12/2011
2	Prion Diseases (Transmissible Spongiform Encephalopathies) 02/2012 - 08/2005
2	Hypercholesterolemia 04/2005 - 04/2004
2	Movement Disorders (Movement Disorder) 12/2003 - 08/2003
1	Epilepsy (Aura) 04/2022
1	Ischemic Stroke 12/2021
1	Frontotemporal Dementia (Semantic Dementia) 10/2021
1	Color Vision Defects (Color Blindness) 01/2021
1	Stroke (Strokes) 06/2018
1	Dementia (Dementias) 06/2018
1	Eye Manifestations (Manifestations, Eye) 06/2018
1	Glaucoma 06/2018
1	Breast Neoplasms (Breast Cancer) 01/2016
1	Retinal Degeneration 02/2015
1	Neoplasms (Cancer) 09/2014
1	Thrombosis (Thrombus) 11/2013

Drug/Important Bio-Agent (IBA)

46	Amyloid (Amyloid Fibrils)IBA 01/2021 - 04/2002
38	Prealbumin (Transthyretin)IBA 01/2021 - 05/2003
36	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2003
15	tafamidisIBA 01/2022 - 01/2008
11	Peptides (Polypeptides)IBA 01/2021 - 10/2004
9	GelsolinIBA 10/2013 - 11/2003
8	Glucosylceramidase (Glucocerebrosidase)IBA 08/2014 - 06/2005
7	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 01/2022 - 04/2002
7	EnzymesIBA 01/2021 - 11/2002
7	Pharmaceutical PreparationsIBA 01/2021 - 12/2006
6	Amyloid beta-PeptidesIBA 11/2017 - 10/2004
6	Diflunisal (Dolobid)FDA Link 12/2013 - 05/2004
4	Protein AggregatesIBA 10/2021 - 03/2004
4	Biomarkers (Surrogate Marker)IBA 01/2021 - 09/2017
4	Biological ProductsIBA 04/2011 - 10/2005
3	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 01/2019
3	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 01/2020 - 11/2006
3	ProteomeIBA 01/2020 - 12/2011
3	LipidsIBA 01/2016 - 04/2004
3	LigandsIBA 08/2011 - 12/2005
3	GlycosaminoglycansIBA 04/2011 - 02/2006
3	alpha-SynucleinIBA 05/2007 - 08/2003
3	FurinIBA 10/2004 - 11/2003
2	Glutamic Acid (Glutamate)FDA Link 12/2021 - 12/2003
2	Complement System Proteins (Complement)IBA 12/2021 - 12/2011
2	SynucleinsIBA 10/2021 - 01/2021
2	Valine (L-Valine)FDA Link 11/2013 - 08/2011
2	Thyroxine (Levothyroxine)FDA LinkGeneric 04/2013 - 12/2006
2	fibulinIBA 11/2012 - 12/2011
2	ApolipoproteinsIBA 12/2011 - 05/2007
2	AcidsIBA 12/2011 - 05/2004
2	Blood Proteins (Serum Proteins)IBA 08/2011 - 01/2008
2	Amyloidogenic ProteinsIBA 02/2011 - 12/2002
2	CalciumIBA 06/2010 - 02/2008
2	GenisteinIBA 06/2010 - 10/2005
1	Ion Channels (Ion Channel)IBA 04/2022
1	gamma-Aminobutyric Acid (GABA)IBA 04/2022
1	Retinaldehyde (Retinal)IBA 01/2021
1	ImmunosorbentsIBA 01/2021
1	Activating Transcription Factor 6IBA 01/2021
1	AlbuminsIBA 11/2019
1	SolutionsIBA 01/2019
1	Congo RedIBA 10/2018
1	diphosphoric acid (pyrophosphoric acid)IBA 10/2018
1	Technetium (Technetium 99m)IBA 10/2018
1	tau Proteins (tau Protein)IBA 10/2018
1	Peptide Hydrolases (Proteases)FDA Link 10/2016
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2016
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2016
1	Pharmacologic ActionsIBA 01/2016
1	Messenger RNA (mRNA)IBA 01/2016
1	Methionine (L-Methionine)FDA Link 11/2013
1	FluoridesIBA 04/2013

Therapy/Procedure

9	Therapeutics 12/2021 - 01/2008
7	Liver Transplantation 06/2018 - 03/2003
2	Drug Therapy (Chemotherapy) 06/2016 - 09/2014
1	Complementary Therapies (Alternative Medicine) 01/2019
1	Aftercare (After-Treatment) 06/2018
1	Precision Medicine 01/2015